Abstract
The BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with coronary artery disease and left ventricULar systolic dysfunction) study assessed the morbidity and mortality benefits of the HR-lowering agent ivabradine. The placebo arm of the BEAUTIFUL trial was a large cohort of patients with stable coronary artery disease (CAD) and left ventricular systolic dysfunction. A subanalysis in the placebo group tested the hypothesis that elevated resting HR at baseline was a marker for subsequent cardiovascular death and morbidity. The primary aim of the study was to test whether lowering the HR with ivabradine reduced cardiovascular death and morbidity in patients with CAD and left ventricular systolic dysfunction. In the overall analysis, reduction in HR with ivabradine did not improve cardiac outcomes compared with placebo. The most important finding of the study was that patients with high baseline HR had an increase in serious cardiovascular events including death (34%), hospital admission secondary to congestive heart failure (53%), acute myocardial infarction (46%), or revascularization procedure (38%). In addition, in the subset analysis focusing on patients with baseline HR ≥70bpm and left ventricular ejection fraction <40% the agent resulted in a 36% decrease in hospital admissions secondary to fatal and nonfatal myocardial infarction and a 30% decrease in coronary revascularization. The first practical implication from the study includes that baseline HR should be recorded in addition to other risk factors such as BP and lipid profile, in the follow-up of patients with CAD. Attempts should be made to achieve HR <70 bpm by cardiac rehabilitation and routine use of appropriately dosed β-blockers. Despite the neutral results obtained in the BEAUTIFUL study, ivabradine could be administered to the subgroup of patients in whom HR <70 bpm is not achieved despite proper dosing of β-blockers and in those in whom β-blockers are contraindicated. Furthermore, in clinical practice, ivabradine may be helpful for patients with stable CAD who have a high HR while receiving β-blockers. Future studies are needed to confirm the hypothesis that single reduction of HR can improve cardiovascular prognosis.
Similar content being viewed by others
References
Fox K, Ferrari R, Tendera M, et al., BEAUTIFUL Steering Committee. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am Heart J 2006; 152: 860–6.
Beautiful Study Group, Ferrari R, Ford I, Fox K, et al. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction-baseline characteristics of the study population. Cardiology 2008; 110: 271–82.
Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967–74.
Jouven X, Empana JP, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352: 1951–8.
Heidland U, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477–82.
Fox M, Borer JS, Camm AJ, et al. Resting Heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823–30.
Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 2007; 28: 3012–19.
Fox K. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807–16.
Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of randomised controlled trial. Lancet 2008; 372: 817–21.
Aboyans V, Criqui MH. Can we improve the cardiovascular risk prediction beyond risk equations in the physician’s office? J Clin Epidemiol 2006; 59: 547–58.
Setakis E, Leufkens HGM, Williams TJ, et al. The effect of heart rate and its changes on cardiovascular disease and mortality. Eur Heart J 2007; 28 (Abstract suppl.): 778.
Theobald H, Wändeil PE. Effect of heart rate on long-term mortality among mean and women. Acta Cardiol 2007; 62: 275–9.
Cacciatore F, Mazzella F, Abete P, et al. Mortality and heart rate in the elderly: role of cognitive impairment. Exp Aging Res 2007; 33: 127–44.
Macfarlane PW, Norrie J. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study. J Electrocardiol 2007; 40: 101–9.
Reil J-C, Danchin N, Thoenes M, et al. Relationship between heart rate and microalbuminuria in patients at high-risk for cardiovascular disease: results from the i-SEARCH study. Eur Heart J 2007; 28 (Abstract suppl.): 246.
Shalnova SA, Deev AD, Vikhireva OV. Resting heart rate as a coronary heart disease and total mortality predictor in Russian men with different CHD status. Eur Heart J 2007; 28 (Abstract suppl.): 778.
Moreau D, Potard D, Mock L, et al. Pre-discharge heart rate measured by 24H Holter monitoring and long term survival after acute myocardial infarction. Data from the RICO survey. Eur Heart J 2007; 28 (Abstract suppl.): 68.
Geha R, Gueret P, Meneveau N, et al. Prognostic impact of discharge heart rate after acute myocardial infarction according to use of beta-blockers: data from the French FAST-MI registry. Eur Heart J 2007; 28 (Abstract suppl.): 68.
Montalescot G, Dallongeville J, van Belle E, et al. STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry). Eur Heart J 2007; 28(11): 1409–17.
Kjekshus JK. The effect of heart rate reduction on survival in heart Failure. Eur Heart J 2007; 28 (Abstract suppl.): 16.
Chonchol M, Goldenberg I, Moss AJ. Risk factors for sudden cardiac death in patients with chronic renal insufficiency and left ventricular dysfunction. Am J Nephrol 2007; 27: 7–14.
Mehta RH, Califf RM, Yang Q, et al. Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock. Am J Cardiol 2007; 99: 793–6.
Stettler C, Bearth A, Allemann S, et al. QTc interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23 year follow-up. Diabetologia 2007; 50: 186–94.
Acknowledgments
Funding for the preparation of this manuscript was provided by Rovi Farmaceuticals. Medical writing assistance was provided by Sofia Perea, PhD on behalf of Wolters Kluwer Pharma Solutions. The authors do not report any conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cortada, J.B., Varela, A. Role of Heart Rate in Cardiovascular Diseases. Am J Cardiovasc Drugs 9 (Suppl 1), 9–12 (2009). https://doi.org/10.2165/1153162-S0-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/1153162-S0-000000000-00000